Indications And Dose
Treatment and prevention of magnesium deficiency ▶BY MOUTH ▶Adult: 10–20 mmol daily, taken as 1–2 sachets of Magnaspartate ® powder.
PDF page 1133
Drug reference
Treatment and prevention of magnesium deficiency ▶BY MOUTH ▶Adult: 10–20 mmol daily, taken as 1–2 sachets of Magnaspartate ® powder.
PDF page 1133
Disorders of cardiac conduction
PDF page 1133
Magnaspartate ® contains magnesium aspartate 6.5 g (10 mmol Mg2+)/sachet.
PDF page 1134
→Appendix 1: magnesium
PDF page 1133
▶Uncommon Diarrhoea. faeces soft ▶Rare or very rare Fatigue. hypermagnesaemia ▶Frequency not known Gastrointestinal irritation SIDE-EFFECTS, FURTHER INFORMATION Side-effects generally occur at higher doses; if side-effects (such as diarrhoea) occur, consider interrupting treatment and restarting at a reduced dose. Overdose Symptoms of hypermagnesaemia may include nausea, vomiting, flushing, thirst, hypotension, drowsiness, confusion, reflexes absent (due to neuromuscular blockade), respiratory depression, speech slurred, diplopia, muscle weakness, arrhythmias, coma, and cardiac arrest.
PDF page 1133
Avoid in severe impairment (eGFR less than 30 mL/minute/1.732).
PDF page 1133
Dissolve sachet contents in 50–200 mL water, tea or orange juice and take immediately.
PDF page 1133
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: powder Powder EXCIPIENTS: May contain Sucrose ▶Magnesiocard (Imported (Germany)) Magnesium (as Magnesium aspartate hydrochloride) 121.5 mg Magnesiocard (magnesium 5mmol) oral powder 5g sachets Blood and nutrition | 50 sachet s ▶Magnaspartate (KoRa Healthcare) Magnesium (as Magnesium aspartate) 243 mg Magnaspartate 243mg (magnesium 10mmol) oral powder sachets | 10 sachet P £9.45 DT = £8.95
PDF page 1134
Patients and carers should be given advice on how to administer magnesium aspartate powder.
PDF page 1134
10–20 mmol daily, taken as 1–2 sachets of
First-line fragment. Read the complete Indications and Dose section above.
PDF page 1133